No abstract

embryo. Multilevel models were used for analysis with p< .05 showing significance.RESULTS: The mean (AE SD) patient ages in years for the euploid and aneuploid groups were 36.4 AE 4.7 and 36.8 AE 3.9, respectively. Our data showed a number of statistically significant metabolic differences when comparing euploid versus aneuploid embryos. Comparing euploid versus all combined aneuploid embryos demonstrated significant metabolic differences in NADH-F (p< .03) and FAD-I (p< .01). Furthermore, comparing euploid versus the grouped chromosomal aneuploidies, NADH-F (p< .05), FAD-I (p< .01), and redox ratio (p< .04) showed significant metabolic differences.CONCLUSIONS: FLIM has identified significant metabolic differences between euploid and aneuploid embryos. These findings provide preliminary evidence that FLIM may be a useful non-invasive clinical tool. Additional data is required to elucidate the true directional relationship between ploidy status and metabolism. Further studies are planned to determine if metabolic signatures via FLIM can assist in clinical embryo selection.SUPPORT: Supported by the Blavatnik Biomedical Accelerator Grant at Harvard University. Becker and Hickl GmbH and Boston Electronics sponsored research with the loaning of equipment for FLIM.

Objective-To evaluate the association between pharmacological therapy for urgency urinary incontinence (UUI) and sleep quality.